Literature DB >> 1419774

Comparative teratogenicity of nine retinoids in the rat.

J A Turton1, G B Willars, J N Haselden, S J Ward, C E Steele, R M Hicks.   

Abstract

he comparative teratogenicity of nine retinoids in Wistar rats was investigated. The compounds studied and dose levels tested (mg/kg) were: all-trans-retinoic acid (TRA), 6.25, 12.5, 25, 50, 100; etretinate (ETR), 25, 50; acitretin (ACIT), 25, 50; 13-cis-retinoic acid (13CRA), 100, 200; and five retinamides, each at 300 and 600 mg/kg, N-(4-hydroxyphenyl)-retinamide (4HPR); N-tetrazol-5-ylretinamide (TZR); N-butylretinamide (NBR); N-ethylretinamide (NER); 13-cis-N-ethylretinamide (13CNER). Retinoids were administered by oral intubation on days 10 and 11 post coitum (p.c.). Dams were killed on day 22 p.c. and examinations carried out to assess teratogenic potential. TRA, ETR, ACIT, 13CRA and 4HPR increased the incidence of resorptions. The incidence of abnormal fetuses, irrespective of the specific abnormalities induced, was markedly increased (50-100%) by TRA, ETR, ACIT, 13CRA and 4HPR, whereas TZR and NBR caused moderate increases (20-50%), and NER and 13CNER induced mild increases (10-20%). The incidences of CNS, craniofacial and urinogenital defects were generally high with TRA, ETR, ACIT and 13CRA. Cardiac vessel defects were markedly increased by 4HPR. Using a number of criteria, a generalized ranking order of the toxicity of the compounds was drawn up: TRA > ETR > ACIT > 13CRA > 4HPR > TZR identical to NBR > NER identical to 13CNER. The ranked order of relative in-vivo teratogenicity for the nine retinoids is compared with a previously reported in-vitro assessment of the compounds using a rat whole embryo culture technique.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1419774      PMCID: PMC2002014     

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  38 in total

1.  Morphogenesis of malformations in hamsters caused by retinoic acid: relation to dose and stage at treatment.

Authors:  R E Shenefelt
Journal:  Teratology       Date:  1972-02

2.  Overview of In Vitro Teratogenicity Testing: aspects of validation and application to screening.

Authors:  G L Kimmel; K Smith; D M Kochhar; R M Pratt
Journal:  Teratog Carcinog Mutagen       Date:  1982

3.  Chondrogenesis: a model developmental system for measuring teratogenic potential of compounds.

Authors:  J R Hassell; E A Horigan
Journal:  Teratog Carcinog Mutagen       Date:  1982

4.  Embryonic limb bud organ culture in assessment of teratogenicity of environmental agents.

Authors:  D M Kochhar
Journal:  Teratog Carcinog Mutagen       Date:  1982

5.  Culture of whole rodent embryos in teratogen screening.

Authors:  A G Fantel
Journal:  Teratog Carcinog Mutagen       Date:  1982

6.  Modification and standardization of the culture of early postimplantation embryos for toxicological studies.

Authors:  S Klug; C Lewandowski; D Neubert
Journal:  Arch Toxicol       Date:  1985-12       Impact factor: 5.153

Review 7.  In vitro testing of teratogenic agents using mammalian embryos.

Authors:  D M Kochhar
Journal:  Teratog Carcinog Mutagen       Date:  1980

8.  Developmental effects of isotretinoin and 4-oxo-isotretinoin: the role of metabolism in teratogenicity.

Authors:  D M Kochhar; J D Penner
Journal:  Teratology       Date:  1987-08

9.  Retinoid toxicity.

Authors:  J A Turton; R M Hicks; J Gwynne; R Hunt; C M Hawkey
Journal:  Ciba Found Symp       Date:  1985

10.  Whole embryo culture: a screening technique for teratogens?

Authors:  T W Sadler; W E Horton; C W Warner
Journal:  Teratog Carcinog Mutagen       Date:  1982
View more
  5 in total

1.  Pharmacological inhibition of lipofuscin accumulation in the retina as a therapeutic strategy for dry AMD treatment.

Authors:  Konstantin Petrukhin
Journal:  Drug Discov Today Ther Strateg       Date:  2013

Review 2.  Novel therapeutics for Stargardt disease.

Authors:  Louise J Lu; Ji Liu; Ron A Adelman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-03-11       Impact factor: 3.117

3.  A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis.

Authors:  Nicoleta Dobri; Qiong Qin; Jian Kong; Kazunori Yamamoto; Zhao Liu; Gennadiy Moiseyev; Jian-Xing Ma; Rando Allikmets; Janet R Sparrow; Konstantin Petrukhin
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-07       Impact factor: 4.799

4.  Developmental abnormalities in cultured mouse embryos deprived of retinoic by inhibition of yolk-sac retinol binding protein synthesis.

Authors:  C Båvik; S J Ward; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

5.  Estrogen receptor alpha (ERα)-mediated coregulator binding and gene expression discriminates the toxic ERα agonist diethylstilbestrol (DES) from the endogenous ERα agonist 17β-estradiol (E2).

Authors:  Aziza Hussein Bakheit Adam; Laura H J de Haan; Ignacio Miro Estruch; Guido J E J Hooiveld; Jochem Louisse; Ivonne M C M Rietjens
Journal:  Cell Biol Toxicol       Date:  2020-02-22       Impact factor: 6.691

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.